Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content.
Primary Sources
White House MFN Drug Pricing Deals Raise Major Questions for Medicaid ...
The White House has announced agreements with Pfizer and AstraZeneca to extend "most-favoured-nation" (MFN) drug pricing to all U.S. state Medicaid programmes, yet pivotal implementation details remain undisclosed. Under the terms highlighted by the Administration, both manufacturers will offer their products at prices no higher than those in other developed countries, a move intended to ...
Press Releases | News | Eli Lilly and Company
Today, Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound® (tirzepatide) KwikPen® for single-patient use will be available at LillyDirect® and major pharmacies nationwide, starting at $299 per month for the 2.5 mg dose.
White House shares legislative text of MFN drug bill with drugmakers - STAT
White House shares drug pricing legislation with pharma companies for feedback while lobbying a reluctant Congress to turn voluntary price deals into law.
Lilly unveils $27bn reshoring drive around four new plants
Lilly's announcement comes just a few days after Lilly's chief executive, David Ricks, and other pharma leaders had a meeting with Trump at the White House, at which the tariff and reshoring ...
